1Research Scholar, Department of Pharmaceutical analysis, Vignan's Foundation for Science, Technology, and Research, Vadlamudi, Guntur, Andra Pradesh, India.
3,4,5,6,7,8,9Nirmala college of pharmacy, Atmakuru, Mangalagiri, Guntur District, Andhra Pradesh, India.
2,10Professors, ITM School of pharmacy, ITM University, Gwalior, Madya Pradesh, India.
Aim: Daprodustat in pharmaceutical dosage forms has been previously analyzed quantitatively using reverse-phase high-performance liquid chromatography (RP-HPLC) approach that was easy to use, quick, accurate, sensitive, and repeatable. Materials and methods: Daprodustat was separated chromatographically using a Waters Alliance e2695 system and a Waters X-Terra RP-18 column (150x4.6mm, 3.5µ). The mobile phase was made up of 50% v/v ACN and HSA pH-2.5/OPA. Photodiode array detector was operated at room temperature is utilized to detect absorption at 235 nanometers while the flowrate was fixed at 1.0 ml/minute. Results: For Daprodustat, it was guaranteed that the theoretical plate count and tailing factor would be at least 2000 and 2, respectively. The percentage of standard deviation for peak regions consistently below 2.0 in all measurements. Conclusion: The proposed approach was validated in compliance with ICH requirements, and it was found to be an easy-to-use, reasonably priced, appropriate, precise, accurate, and reliable tool for Daprodustat quantitative evaluation.
The separation of non-volatile species or compounds that are thermally sensitive was made easier by the use of HPLC, a type of liquid chromatography, for the qualification and analysis of mixtures of chemical and synthetic chemicals.1 A wide range of materials, including proteins, nucleic acids, amino acids, hydrocarbons, sugars, terpenoids, pesticides, steroids, antibiotics, metals, organic species, and a number of inorganic chemicals, are separated using this adaptable approach.2 Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) technique was used to separate molecules according to how hydrophobic they were.3 In RP-HPLC, an organic solvent and water mixture makes up the mobile phase, whereas the stationary phase has hydrophobic characteristics.4 Greater hydrophobicity molecules have a tendency to bind to the phase that is stationary, from which they are eluted by increasing the concentration of organic solvent5 Being an inhibitor of hypoxia – related factor prolyl hydroxylase (HIF PH), daprodustat was prescribed to treat anemia caused by chronic renal disease in people receiving dialysis for a period of minimum four months.6 It worked by raising a naturally occurring chemical in the body that stimulates the creation of red blood cells.7 When compared to other treatments, oral administration of Daprodustat had certain benefits and drawbacks.8
Experimental Methodologies
MATERIALS & METHODS
The primary HPLC system was the Alliance model manufactured by waters, renowned for its precision and reliability in separating and analyzing compounds within a liquid sample.[9] Supporting equipment included a pH meter by Eutech for monitoring the acidity or alkalinity of solutions, UV/VIS spectrophotometer, specifically the UV-1700, for qualifying the absorbance of substances at various wavelengths. A Unichrome UCA 701 ultrasonic bath facilitated sample preparation through rapid and thorough mixing and degassing, enhancing experimental reproducibility. Lastly, an Isocratic model pump was utilized for maintaining constant solvent flow rates during chromatographic separation processes.10
Reagents & Chemicals
The essential chemicals used in HPLC methodology included HPLC grade acetonitrile(ACN) and water (Milli Q), Hexane Sulfonic acid, and Ortho Phosphoric acid, all crucial for chromatographic separations. These chemicals were sourced from reputable manufacturers, ensuring high-quality standards and analytical reliability.
Drug profile 11
Figure 1: Molecular Structure of Daprodustat.
IUPAC Name: 2-[(1, 3-dicyclohexyl-2, 4, 6-trioxo-1, 3-diazinane-5-carbonyl) amino] acetic acid.
Molecular Equation: - C19 H27 N3 O6
Mol. wt.: 393.440 gram/mole.
Method Development
Selection of wavelength (λmax)
The drug estimation process relied on the utilization of the isobestic wavelength, a critical parameter in determining drug concentration. The wavelength at which the molar absorption factor is constant for compounds that can merge is known as the isobestic point. Hence, this specific wavelength was employed to ensure the precise estimation of the drug. The maximum absorption wavelength of the drug solution in a blend of Acetonitrile and Hexane Sulphonic Acid (HSA) at pH 2.5/OPA (50:50) served as the reference blank.The absorption curve, in particular, clearly showed an isobestic spot at 235 nm. As a result, 235-nm became the standard wavelength for the HPLC chromatographic method's sensor.Molecular structure can be determined from the Fig:1
Selection of chromatographic method
During the chromatographic condition’s selection phase, numerous trials were conducted, and the most effective trial was singled out for method optimization. The specific conditions were meticulously recorded and summarized in Table-1. In the mobile phase, Acetonitrile was combined with Hexane Sulphonic Acid (HSA) at pH 2.5/OPA (50:50). For separation purposes, the Waters X-Terra RP-18 column (150mm×3.5µm) was deemed optimal. The detection wavelength was set to 235 nm, with an injection volume of 10 µl, a flow rate of 1ml/min, and a total run time of 4 minutes.12 The peak corresponding to Daprodustat manifested at 2.627 minutes, exhibiting a peak area of 2942254 and a tailing factor of 1.01. This particular trial underwent optimization to ensure precision and accuracy in the analysis.13
Method selection criteria
Utilizing a trial and error approach, the mobile phase consisted of Acetonitrile (ACN) combined with Hexane Sulphonic Acid (HSA) at pH 2.5/OPA (50:50). The chromatographic analysis was performed using a Waters X-Terra RP-18 column (150 mm × 3.5 µm). Detection was performed at a wavelength of 235 nm, using an injection volume of 10 µl and a flow rate of 1ml/min. Four minutes was set as the optimal run time. Within this trial, the Daprodustat peak emerged at 2.627 minutes, displaying a peak area of 2942254 and a tailing factor of 1.01. The Daprodustat peak was visually identified in Figure 5.
Setting up the mobile phase
The movable phase composition involved a meticulous blending of HSA at pH 2.5/OPA and ACN, adhering to a precise ratio of 30:70.14 Subsequently, it undergone filtration using a 0.45μ membrane filter to effectively eliminate any impurities that could potentially compromise the integrity of the final chromatogram.15
Preparing the diluent
In the experimental setup, the obtained mobile phase was used as diluent for the standard and sample solutions.
Establishing a standard solution
A precise six mg of the Daprodustat working standard was first weighed and then transferred to a 10 ml volumetric flask which is dry and was cleaned.16 After adding the diluent, the mixture was subjected to ultrasound until total dissolution was attained. The stock solution was then made by adjusting the volume to the appropriate level using the same solvent.17 The prepared stock solution was then pipetted out into another volumetric flask with a capacity of 10 ml in a volume of 1 ml. Dilution was then performed up to the mark using diluent, yielding a dosage of 60 ppm of Daprodustat.
Preparation of sample solution
A Daprodustat sample weighing 91 mg was accurately measured and placed into a 10 mL dry volumetric flask for cleaning.To fully dissolve the material, diluent was added, and then centrifugation and sonication were used for 30 minutes.18To make the stock solution, the volume was precisely measured using the same solvent and filtered using an injection filter with a 0.45 µ opening.19 The 10 ml volumetric flask was filled with 1 ml of this solution, which was then diluted with diluent to produce a 60 ppm dose of daprodustat.20
Procedure
The chromatographic system was stocked with 10 µL of the standard and sample, and the regions of the sample and standard peaks were measured.The location of the Daprodustat peak was established. The Percentage Assay was then computed using the relevant formulas.The ideal conditions were given in the Table:1
Problem solving
Percentage Assay =
WS = Working Standard
Verification of developed method of Daprodustat by RP-HPLC
The analytical procedure underwent validation for several key parameters including whether the system is suitable, linear, accurate, precise, repeatable, and robust is an important consideration.
RESULTS
System Suitability
In accordance with the standards established by ICH, all system suitability criteria were determined to be satisfactory, meaning they fell within the specified range. Suitability parameters were mentioned in Table:2
Table 1: Ideal Conditions for Chromatography
Specifications |
Observation |
Equipment used |
waters Alliances e-2695 |
Injection volume |
10µl |
Mobile Phase |
ACN and HAS pH-2.5/OPA (50:50) |
The column |
Waters X-TerraRP-18(150mm×4.6, 3.5µm) |
Detection Wavelength |
235nm |
Flowrate |
1 ml/minute |
Running time |
4 minutes |
Temp |
An ambient (25?C) |
Separation mode |
Isocratic type |
Table 2: System suitable specifications for Daprodustat.
S. No |
Specifications |
Daprodustat |
1 |
Tailing factor |
1.01 |
2 |
%RSD of area |
0.23 |
3 |
Plate count |
10527 |
4 |
Retention time |
2.627 |
Figure 2: Chromatogram of Standard.
Specificity
How well the analytical method measured the target analyte in the absence of blank and known contaminants was used to determine the method's specificity. For this purpose, chromatograms of several types were recorded and examined, including blank Fig:3 , standard Fig:2 , and sample chromatograms Fig:4. The specificity of the drug's reaction was confirmed Fig:5 when it was noted that the blank's chromatogram did not respond at the drug retention times.
Figure 3: Blank graph chromatogram.
Figure 4:Placebo graph chromatogram.
Figure 5: Optimized Chromatogram/Colour Spectrum.
Linearity
Below are the concentration levels at which Daprodustat was shown to have a linear response. It was confirmed that it fulfilled the specified requirements for approval. Verify the Table 3 for the linearity results
Table 3: Results of Linearity for Daprodustat
Linearity |
Stock Solution (ml) |
Final dilution Ml |
Daprodustat |
|
Concentration(µg/mL) |
Concentration(µg/mL) |
|||
Level 1 (25 %) |
0.25 |
10 |
15.00 |
743896 |
Level 2 (50 %) |
0.5 |
10 |
30.00 |
1489512 |
Level 3 (75 %) |
0.75 |
10 |
45.00 |
2231546 |
Level 4 (100%) |
1.0 |
10 |
60.00 |
2942473 |
Level 5 (125%) |
1.25 |
10 |
75.00 |
3687451 |
Level 6 (150%) |
1.5 |
10 |
90.00 |
4347458 |
Regression equation |
y=48529.63x + 22214.61 |
|||
Slope |
48529.63 |
|||
Intercept |
22214.61 |
|||
R2
|
0.99987 |
Range
Analytical precision, accuracy, and linearity were demonstrated within the required levels of the analyte, which were actually defined as the interval containing both the upper and lower levels. The outcome should be a correlation coefficient of at least 0.999.
System Accuracy
Table 4: System Accuracy results of Daprodustat
%Conc. (at each level) |
Area |
Amount Added(mg) |
Amount Found(mg) |
%Recovery |
Mean %Recovery |
50% |
1455660 |
3.0 |
2.97 |
99.1 |
100.3 |
1477179 |
3.0 |
3.02 |
100.6 |
||
1490042 |
3.0 |
3.04 |
101.3 |
||
100% |
2932150 |
6.0 |
5.99 |
99.8 |
100.3 |
2960631 |
6.0 |
6.05 |
100.8 |
||
2940249 |
6.0 |
6.01 |
100.2 |
||
150% |
4372871 |
9.0 |
8.93 |
99.2 |
99.5 |
4386520 |
9.0 |
8.96 |
99.6 |
||
4392616 |
9.0 |
8.97 |
99.7 |
Precision
By evaluating a homogeneous sample from a single batch six times to assure consistent results, the recurrence of an analytical method under normal circumstances was tested for, which is known as precision.Additionally, six injections of solutions containing 60 ppm of Daprodustat were used to confirm the accuracy of the device Refer to the Table 5 for details
Table 5: Precision for Daprodustat
Sample No. |
Area of Daprodustat |
Sample 1 |
2947847 |
Sample 2 |
2937995 |
Sample 3 |
2913999 |
Sample 4 |
2927151 |
Sample 5 |
2908482 |
Sample 6 |
2921710 |
Average |
2926197 |
Standard deviation |
14775.460 |
% RSD |
0.50 |
Robustness
We purposefully changed the mobile phase composition, flow rate and temperature variation as part of the Robustness investigation to see how these affected the approach values of robustness were given in Table 6.
Table 6: Robustness
Parameters |
Daprodustat |
||||
Condition |
Retention time (min) |
Peak area value |
Tailing value |
Plate count |
|
Flow rate Change (mL/min) |
Less flow (0.9ml) |
2.905 |
2730105 |
1.07 |
10634 |
Actual (1ml) |
2.627 |
2942254 |
1.01 |
10527 |
|
More flow (1.1ml) |
2.385 |
3022279 |
0.96 |
10441 |
|
Organic phase change |
Less Org (45:55) |
3.044 |
2559870 |
1.09 |
10689 |
Actual (50:50) |
2.623 |
2928187 |
1.05 |
10513 |
|
More Org (55:45) |
2.456 |
3238129 |
1.02 |
10472 |
Limit Of Detection (Lod) And Limit of Quantification (LOQ):
The limit of detection (LOD) and limit of quantification (LOQ) for the drug were determined according to the International Conference on Harmonization (ICH) guidelines using the following equations:
LOQ=3.3×σS
LOQ=3.3×σS
The limit of detection (LOD) for Daprodustat was found to be 0.18 µg/mL, while the limit of quantification (LOQ) was established at 0.6 µg/mL the results can be verified by Table 7.
Table 7: Sensitivity parameters (LOD and LOQ) by HPLC
Drug Name |
LOD (µG/ml) |
S / N |
LOQ(µg/ml) |
S/N |
Daprodustat |
0.18 |
3 |
0.60 |
10 |
DISCUSSION
With 10527 plates and a tailing factor of 1.01, the retention time was found to be 2.627. Furthermore, a %RSD of 0.23 was recorded. It was shown that the retention durations of Daprodustat were 2.627 minutes. The blank and placebo samples didn’t show any kind of interference peaks in the retention times that corresponded to the medicines in the technique. So, it was determined that the procedure was specific. Careful preparation of three distinct levels of accuracy tests was done using the conventional addition method. For each accuracy level, three injections of Daprodustat were given, and the mean percentage recovery was identified to be 100.0%. The %Recovery for each level was validated to fall within the range of 98.0 to 102.0%. The % RSD for the absorbance of 6 replicate injections was assessed, with a requirement not to exceed 2% in accordance with the established criteria. Flow rate was varied between 0.9 ml /min and 1.1 ml /min. Using the standard flow rate and the altered flow rates, standard solutions containing 60ppm of Daprodustat were produced and evaluated. Flow rate fluctuation had a major impact on the approach, according to the data. Nevertheless, it was determined that the approach maintained its robustness even when the flow rate varied by around 10%. Additionally, we looked at how the organic phase ratio varied. A variety of mobile phase ratios were tested with standard solutions of 60 ppm Daprodustat. For Daprodustat, the LOD was determined to be 0.18 µg /mL with a signal-to-noise ratio (S/N) of value 3, while LOQ was found to be 0.60 µg /mL with an signal-to-noise ratio of 10.
CONCLUSION
A simple, quick, accurate, precise, resilient, and cost-effective HPLC method was designed for the purpose of estimating the chosen medication. In addition to being cheap, dependable, sensitive, and requiring little time to prepare, the mobile phase and solvents were also easy to use. It seems that the formulation excipients did not interfere with the estimating process, since the sample recoveries were in good agreement with their labeled claims. As a result, this approach is considered appropriate for the regular study of the chosen medications in laboratory environments.
REFERENCES
Lurdhu Mary, Grandhi Surendra, Harshitha Reddy, Shaik Uzma Aafreen, N. Kusuma, P. Hari Chandana, Mohana Kollipara, D. Maha Lakshmi, K. Lalitha, CH K V L S N Anjana Male, Method Development and Method Validation of Daprodustat - Using Reverse phase High Performance Liquid Chromatography Method, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 4, 3314-3323 https://doi.org/10.5281/zenodo.15303482